NATURAL PRODUCT FROM GELATINOUS ZOOPLANKTON

来自凝胶状浮游动物的天然产品

• 批准号: 3493200
• 负责人: JANICE L THOMPSON
• 金额: $ 5万
• 依托单位: CALBIOMARINE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-07-12 至 1993-04-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493200
• 关键词: Cnidaria; Invertebrata; Mollusca; Tunicata; antineoplastics; biological products; chromatography; clone cells; cytotoxicity; drug screening /evaluation; marine biology; mass spectrometry; neoplastic cell; nuclear magnetic resonance spectroscopy; solvent extraction

The goal of this project is to systematically explore the gelatinous zooplankton for antitumor and other biological activities. The following invertebrate groups will be collected: Cnidaria (hydromedusae, hydroids, scyphomedusae, siphonophores), Ctenophora, Mollusca (pteropods, heteropods, nudibranchs), and Urochordata (tunicates, doliolids, pyrosomes). Phase I will concentrate on collecting 10% of a systematic program total of 150-200 species and on evaluating the cost-effectiveness of several collection and recollection methods (bucket, trawl, and SCUBA). Samples will be extracted and screened against a panel of 5-6 human tumor cell lines. Active extracts will be further fractionated according to biological activity, and described chemically. Phase II will continue this work and the NCI will be given the opportunity to screen the collection. It is expected that new chemical entities, with important pharmaceutical activities, will be described and patented; they will be licensed to the government or pharmaceutical companies for development. The evaluation of gelatinous zooplankton represents a new opportunity for drug discovery. Only a few species have been evaluated due to the perceived technical difficulty of collecting and recollecting zooplankton in kilogram quantities. These planktonic species are likely sources of bioactive metabolites since their benthic (bottom-living) relatives have yielded many bioactive metabolites.

该项目的目标是系统地探索凝胶状 浮游动物具有抗肿瘤和其他生物活性。 下列 将收集无脊椎动物群体： 刺胞动物（水螅科、水螅、 scyphomedusae、管水母目）、栉水母目、软体动物门（翼足类、异足类、 裸鳃类）和尾索动物类（被囊类、多利奥利类、火体类）。 第一阶段 将集中收集150-200个系统程序中的10% 物种以及评估几种收集和收集的成本效益 回收方法（桶式、拖网式和水肺式）。 样品将是 提取并针对一组 5-6 个人类肿瘤细胞系进行筛选。 活性提取物将根据生物学特性进一步分级 活性，并进行化学描述。 第二阶段将继续这项工作 NCI 将有机会筛选该藏品。 这是 预计新的化学实体，具有重要的制药作用 活动，将被描述并获得专利；他们将被许可给 政府或制药公司进行开发。 凝胶状浮游动物的评估为研究提供了新的机遇 药物发现。 由于以下原因，仅对少数物种进行了评估 收集和回收浮游动物的技术难度 以公斤为单位。 这些浮游物种可能是 生物活性代谢物，因为它们的底栖（生活在底层）亲戚具有 产生了许多具有生物活性的代谢物。